» Articles » PMID: 25452335

Meclofenamic Acid Selectively Inhibits FTO Demethylation of M6A over ALKBH5

Overview
Specialty Biochemistry
Date 2014 Dec 3
PMID 25452335
Citations 322
Authors
Affiliations
Soon will be listed here.
Abstract

Two human demethylases, the fat mass and obesity-associated (FTO) enzyme and ALKBH5, oxidatively demethylate abundant N(6)-methyladenosine (m(6)A) residues in mRNA. Achieving a method for selective inhibition of FTO over ALKBH5 remains a challenge, however. Here, we have identified meclofenamic acid (MA) as a highly selective inhibitor of FTO. MA is a non-steroidal, anti-inflammatory drug that mechanistic studies indicate competes with FTO binding for the m(6)A-containing nucleic acid. The structure of FTO/MA has revealed much about the inhibitory function of FTO. Our newfound understanding, revealed herein, of the part of the nucleotide recognition lid (NRL) in FTO, for example, has helped elucidate the principles behind the selectivity of FTO over ALKBH5. Treatment of HeLa cells with the ethyl ester form of MA (MA2) has led to elevated levels of m(6)A modification in mRNA. Our collective results highlight the development of functional probes of the FTO enzyme that will (i) enable future biological studies and (ii) pave the way for the rational design of potent and specific inhibitors of FTO for use in medicine.

Citing Articles

The role of mA modification during macrophage metabolic reprogramming in human diseases and animal models.

Wang H, Xu P, Yin K, Wang S Front Immunol. 2025; 16:1521196.

PMID: 40066451 PMC: 11891544. DOI: 10.3389/fimmu.2025.1521196.


Novel Insight of N6-Methyladenosine in Cardiovascular System.

Zhang H, Lu W, Tang H, Chen A, Gao X, Zhu C Medicina (Kaunas). 2025; 61(2).

PMID: 40005339 PMC: 11857502. DOI: 10.3390/medicina61020222.


Epitranscriptomics in the Glioma Context: A Brief Overview.

Santamarina-Ojeda P, Fernandez A, Fraga M Cancers (Basel). 2025; 17(4).

PMID: 40002173 PMC: 11853273. DOI: 10.3390/cancers17040578.


TDP-43/ALKBH5-mediated mA modification of CDC25A mRNA promotes glioblastoma growth by facilitating G1/S cell cycle transition.

Zhang Y, Xie S, Li W, Gu J, Zhang X, Ni B MedComm (2020). 2025; 6(3):e70108.

PMID: 39974663 PMC: 11836349. DOI: 10.1002/mco2.70108.


Exploring m6A modifications in gastric cancer: from molecular mechanisms to clinical applications.

Li P, Fang X, Huang D Eur J Med Res. 2025; 30(1):98.

PMID: 39940056 PMC: 11823136. DOI: 10.1186/s40001-025-02353-5.


References
1.
. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr. 1994; 50(Pt 5):760-3. DOI: 10.1107/S0907444994003112. View

2.
Bartzatt R . Anti-inflammatory drugs and prediction of new structures by comparative analysis. Antiinflamm Antiallergy Agents Med Chem. 2012; 11(2):151-60. DOI: 10.2174/187152312803305768. View

3.
Falnes P, Klungland A, Alseth I . Repair of methyl lesions in DNA and RNA by oxidative demethylation. Neuroscience. 2006; 145(4):1222-32. DOI: 10.1016/j.neuroscience.2006.11.018. View

4.
Niu Y, Zhao X, Wu Y, Li M, Wang X, Yang Y . N6-methyl-adenosine (m6A) in RNA: an old modification with a novel epigenetic function. Genomics Proteomics Bioinformatics. 2013; 11(1):8-17. PMC: 4357660. DOI: 10.1016/j.gpb.2012.12.002. View

5.
Kruidenier L, Chung C, Cheng Z, Liddle J, Che K, Joberty G . A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature. 2012; 488(7411):404-8. PMC: 4691848. DOI: 10.1038/nature11262. View